ArticleOpen forum infectious diseases2025
Discontinuation of Long-acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study.Advances in therapy · 2026Trial
- What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir/Rilpivirine?AIDS and behavior · 2026Article
- Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics.Open forum infectious diseases · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Little is known about long-acting injectable cabotegravir-rilpivirine discontinuation outside clinical trials. In a large clinic cohort, 1 in 6 people with HIV discontinued long-acting injectable cabotegravir-rilpivirine over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for people with HIV with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.